Loading…
Loading…
NEW YORK--(BUSINESS WIRE)--Central Securities Corporation (NYSE American: CET), a closed-end investment company, today released its Report to Stockholders for the six months ended June 30, 2026. Figures as of June 30, 2026 compared with those of one year ago, are as follows: June 30, June 30, 2026 2025 Net assets per common share $62.11 $57.63 Net assets $1,835,257,298 $1,666,259,626 Shares outstanding 29,549,265 28,913,659 Additional detail.
Paris, France – July 21, 2026 Q2 2026 financial results and conference call Viridien will publish its second quarter 2026 results on Thursday, July 30, after market close. The press release and presentation will be made available on www.viridiengroup.com at 5.45 pm (CET) An English-language conference call is scheduled at 6.00 pm (CET) on the same day Participants must register for the conference call by clicking here to receive a dial-in number and PIN code.
LEUVEN, Belgium, July 01, 2026 (GLOBE NEWSWIRE) -- MATERIALISE NV Technologielaan 153001 LeuvenCompany number: 0441.131.254RPR Leuven
STOCKHOLM, June 24, 2026 /PRNewswire/ -- Autoliv Inc., plans to publish its Financial Report for the second quarter 2026 on Friday, July 17, 2026 at 12:00 Central European Time (CET). The report will be available at www.autoliv.com In addition, a teleconference will take place the same day.
REGULATED INFORMATION June 19, 2026, 10:30pm CET / 4:30pm ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 9, 2026 The board of directors of the Company is pleased to invite its securities holders to attend the extraordinary shareholders' meeting of the Company, to be held on Thursday, July 9, 2026 at 2:00 p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time.
NEW YORK--(BUSINESS WIRE)--The Board of Directors of Central Securities Corporation (NYSE American: CET), a closed-end investment company, today declared the following dividend: Class of Stock Rate Ex- and Record Date Payment Date Common Stock $0.31 6/12/2026 6/26/2026 Of the $0.31 per share to be paid on June 26, 2026, $0.06 is expected to be taxable as ordinary income and $0.25 is expected to be taxable as long-term capital gain. The final tax breakdown of all amounts paid during 2026.
STOCKHOLM, May 13, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's first quarter report for January - March 2026 on Wednesday, May 20, 2026, at 8:00 a.m. CET. In conjunction with the report, BioArctic invites investors, analysts and media to a webcast (in English) on May 20, at 9:30 a.m CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, together with colleagues, will present and comment on the first quarter report, followed by a Q&A session.
Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM (Euronext & NASDAQ: LKFT) Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026 Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation priorities Year-end 2026 cash and financial investments balance expected to be approximately €2B Management to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium ; May 6, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the first quarter of 2026 and provided a business update. “Having joined the company just one year ago, I'm thrilled with our progress. I am looking forward to consummating our partnership with Gilead and adding Ouro Medicines' talented team and its portfolio of programs to our Company, including the potential first and best in class T cell engager in autoimmune diseases, gamgertamig (OM336). We are excited that our Company is rebranding as Lakefront Biotherapeutics as this name reflects our Company's strategic evolution,” said Henry Gosebruch, Chief Executive Officer of Galapagos. Aaron Cox, Chief Financial Officer of Galapagos, added, “Following the anticipated use of cash to fund our collaboration with Gilead concerning its acquisition of Ouro Medicines, the Company will remain robustly capitalized and will have increased flexibility, including the ability to spend up to $500 million for business development independent of Gilead and not subject to our 2019 Option, License, and Collaboration Agreement with Gilead. This would also include the potential to use up to $150 million of that $500 million for share repurchases to the extent that we have available distributable reserves. In addition to the upfront consideration of $837.5 million, we anticipate additional 2026 Ouro-related cash expenditures to be in the range of €60-75 million, inclusive of R&D costs, one-time transaction costs and assuming a mid-year closing of the transaction.” First Quarter 2026 Business Update